Quinine + Clindamycin

Quinine + clindamycin is an antimalarial combination therapy recommended by the World Health Organization (WHO) as an alternative non-artemisinin-based treatment for uncomplicated falciparum malaria[1]. This combination is particularly valuable for treating malaria in children and pregnant women, in whom tetracyclines are contraindicated[2]. ## Mechanism of Action and Efficacy The combination works through complementary mechanisms - quinine acts rapidly against malaria parasites while clindamycin, though slower-acting, provides additional antiparasitic effects through a different mechanism[1]. This allows the quinine treatment course to be shortened to 3 days when combined with clindamycin, potentially improving patient adherence[1]. Clinical studies have demonstrated varying efficacy depending on dosage, duration, and geographic region: - In Thailand, the combination showed 100% cure rates at 28 days follow-up when administered as a 7-day regimen (quinine for 7 days plus clindamycin for 7 days)[2]. - A controlled trial comparing 3-day quinine-clindamycin versus 7-day quinine treatment found the shorter regimen to be well-tolerated and comparable to the longer quinine-only treatment[5]. - However, a study in Kenyan children found poor efficacy with a 3-day low-dose regimen, showing only 44% adequate clinical and parasitological response compared to 97.1% with artemether-lumefantrine[4]. ## Clinical Applications The WHO recommends quinine plus clindamycin for: - First-line treatment of malaria in the first trimester of pregnancy - Second-line treatment for uncomplicated falciparum malaria when artemisinin-based combinations are unavailable[4] Standard dosing recommendations include: - Quinine sulfate: 10 mg/kg body weight (maximum 650 mg) per dose orally every 8 hours for 3-7 days - Clindamycin: 7 mg/kg body weight per dose orally every 8 hours[6] For children under 8 years of age, clindamycin is preferred over doxycycline or tetracycline when combined with quinine[6]. ## Limitations The combination has some notable limitations: - Clindamycin is a slowly acting drug, with parasite clearance times of 4-6 days compared to 2-3 days for other antimalarials or about 1 day for artesunate[3]. - Fever clearance times are similarly slow, ranging from 3-5 days[3]. - The combination appears less effective against Plasmodium vivax than against Plasmodium falciparum[3]. Despite these limitations, quinine plus clindamycin remains an important alternative treatment option, especially in regions with limited access to artemisinin-based combinations and for specific patient populations where other antimalarials are contraindicated.

Other names

quinine-clindamycin